PMID: 9632621Jun 25, 1998Paper

Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis

Infection and Immunity
Y SinghStephen H Leppla

Abstract

Protective antigen (PA) of anthrax toxin is the major component of human anthrax vaccine. Currently available human vaccines in the United States and Europe consist of alum-precipitated supernatant material from cultures of toxigenic, nonencapsulated strains of Bacillus anthracis. Immunization with these vaccines requires several boosters and occasionally causes local pain and edema. We previously described the biological activity of a nontoxic mutant of PA expressed in Bacillus subtilis. In the present study, we evaluated the efficacy of the purified mutant PA protein alone or in combination with the lethal factor and edema factor components of anthrax toxin to protect against anthrax. Both mutant and native PA preparations elicited high anti-PA titers in Hartley guinea pigs. Mutant PA alone and in combination with lethal factor and edema factor completely protected the guinea pigs from B. anthracis spore challenge. The results suggest that the mutant PA protein may be used to develop an effective recombinant vaccine against anthrax.

References

Feb 1, 1988·Infection and Immunity·J W Ezzell, T G Abshire
Jan 1, 1988·Methods in Enzymology·S H Leppla
Aug 1, 1985·Infection and Immunity·B D GreenB E Ivins
May 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·S H Leppla
Jan 1, 1983·Infection and Immunity·P MikesellT M Dreier
Apr 1, 1995·Infection and Immunity·C PezardM Mock
Apr 1, 1962·American Journal of Public Health and the Nation's Health·P S BrachmanN R Ingraham

❮ Previous
Next ❯

Citations

Oct 17, 2003·The Journal of Biological Chemistry·Julie A MussonJohn H Robinson
Sep 1, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Stephen F Little
Sep 23, 2009·Expert Opinion on Biological Therapy·Dennis M KlinmanKoji Tomaru
Nov 10, 2011·Toxins·Zhaochun ChenRobert Purcell
Apr 9, 2001·Infection and Immunity·S ReuvenyB Velan
May 1, 2001·Journal of Toxicology. Clinical Toxicology·B Swanson-Biearman, E P Krenzelok
Mar 4, 2009·Expert Review of Anti-infective Therapy·Jean-Nicolas TournierBradley G Stiles
Apr 20, 2002·Current Opinion in Infectious Diseases·Peter C.B. Turnbull
Sep 9, 2004·Microbiology and Molecular Biology Reviews : MMBR·Holger BarthBradley G Stiles
Feb 8, 2008·Clinical and Vaccine Immunology : CVI·Qingfu Xu, Mingtao Zeng
Jan 5, 2011·Immunological Reviews·Theodor ChitlaruAvigdor Shafferman
Nov 13, 2009·Molecular Microbiology·Justin Kern, Olaf Schneewind
Sep 14, 2012·Science Translational Medicine·Michael P FayEdwin O Nuzum
Jul 13, 2019·Expert Review of Vaccines·Olga A KondakovaOlga V Karpova
May 1, 2001·Biochemical and Biophysical Research Communications·V ChauhanR Bhatnagar
Sep 15, 2005·Vaccine·Mingtao ZengMichael E Pichichero
Nov 30, 2005·Journal of Pharmaceutical Sciences·Ge JiangVincent J Sullivan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.